FAKTOR-OPTIONSSCHEIN - ABCELLERA BIOLOGICS Share Price

Certificat

DE000ME283Y3

Market Closed - Börse Stuttgart 19:44:33 24/05/2024 BST
1.48 EUR -8.64% Intraday chart for FAKTOR-OPTIONSSCHEIN - ABCELLERA BIOLOGICS
Current month-15.43%
1 month-29.86%
Date Price Change
24/05/24 1.48 -8.64%
23/05/24 1.62 +3.18%
22/05/24 1.57 +11.35%
21/05/24 1.41 -2.08%
20/05/24 1.44 +9.09%

Delayed Quote Börse Stuttgart

Last update May 24, 2024 at 07:44 pm

More quotes

Static data

Product typeProduits Exotiques
Buy / SellCALL
Underlying ABCELLERA BIOLOGICS INC.
Issuer Morgan Stanley
WKN ME283Y
ISINDE000ME283Y3
Date issued 18/10/2023
Strike 2.888 $
Maturity Unlimited
Parity 0.55 : 1
Emission price 10
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 19.58
Lowest since issue 1.27
Spread 0.03
Spread %1.86%

Company Profile

AbCellera Biologics Inc. is focused on the development of antibody-based drugs and is committed to improving discovery and development. It is engaged in antibody discovery and development engine is specifically designed to break the barriers of conventional discovery. It provides biotech and pharmaceutical companies with an advantage that empowers them to move quickly, reduce cost, and tackle the toughest problems in drug development. The Company uses the engine to both work with partners to build a large and diversified portfolio of royalty stakes in antibody drugs and to develop its own pipeline of antibody drugs. The Company partners with companies of all sizes, from biotechnology companies to pharmaceutical companies-propelling programs to the clinic, together. It generates a range of diverse antibodies with immunization strategies and single-cell screening.
Sector
-
More about the company

Ratings for AbCellera Biologics Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Consensus: AbCellera Biologics Inc.

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
3.85 USD
Average target price
12.71 USD
Spread / Average Target
+230.24%
Consensus